Trial Profile
A Combined Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Induction and Maintenance Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Ulcerative Colitis
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 28 Jul 2020
Price :
$35
*
At a glance
- Drugs Andecaliximab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 01 Nov 2017 Results presented at the 25th United European Gastroenterology Week
- 19 Jan 2017 This trial has been completed in Belgium (end date: 16 Nov 2016).
- 06 Oct 2016 This trial was completed in Spain, according to Eudra record.